INSCRIPTA® ACQUIRES INFINOME BIOSCIENCES AND SESTINA BIO TO ADVANCE SUSTAINABLE BIOMANUFACTURING
With the addition of Infinome and Sestina Bio, Inscripta adds to its portfolio of cutting-edge technologies for biomanufacturing products for...
Read More
Sestina Bio uses Inscripta’s ONYX® Platform to develop microbial strain ready for scale-up in less than 12 months
Inscripta and Sestina Bio announced successful development of a ready-to-scale microbial strain producing Bakuchiol, a natural retinol replacement.
Read More
KALSEC® PARTNERS WITH INFINOME™ BIOSCIENCES TO SUSTAINABLY DEVELOP AND MANUFACTURE PRECISION FERMENTATION PRODUCTS
Through advanced technology and processes, Infinome is creating sustainable manufacturing solutions for Kalsec.
Read More
Willow Biosciences Incorporates Inscripta’s Onyx® Platform to Expand Strain Engineering Capabilities and Throughput
Willow Biosciences Inc., a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable ingredients along with...
Read More
Aldevron Licenses the Manufacturing of MAD7, a Type-V CRISPR Nuclease From Inscripta
A partnership between two CRISPR pioneers will provide the global scientific community with GMP MAD7™ Nuclease
Read More
Ginkgo Bioworks Adopts Inscripta®’s Onyx® Digital Genome Engineering Platform to Continue Accelerating its Genome Editing Throughput
Inscripta®, the Digital Genome Engineering Company, today announced that Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming,...
Read More
Inscripta® Appoints Kristala Prather, PhD to its Board of Directors
Inscripta adds a distinguished MIT Professor and synthetic biology pioneer, Dr. Kristala Prather, to the Board of Directors.
Read More
Hunterian Medicine® Licenses Inscripta’s MAD7™ Nuclease to Advance Gene Editing Research and Development
Inscripta and Hunterian pioneer new program to provide access to novel CRISPR enzymes for biotherapeutic development
Read More
Amyris Partners with Inscripta® to Enhance Development of Sustainable Ingredients Using the Onyx® Genome Engineering Platform
Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer...
Read More
Inscripta® Announces the First Commercial Shipment of Its Onyx® Digital Genome Engineering Platform and Closes $150 Million in New Financing
GeneMill at the University of Liverpool receives first benchtop Onyx platform in Europe Financing round led by Fidelity and T....
Read More